Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vs-4718. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 known ✓ | Q05397 | 9/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 12/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 9/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.64 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.64 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | PAK4 | O96013 | 1/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | PRKCG | P05129 | 1/20 | 0.64 |
| ▸ | INSR | P06213 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vs-4718 SCHEMBL29493098 | 1.00 | MAPK10 (1.00) | MAPK10MAPK9PTK2CDC7PLK4 | |
| Vs-4718 SCHEMBL29381276 | 1.00 | MAPK10 (1.00) | MAPK10MAPK9PTK2CDC7PLK4 | |
| Vs-4718 SCHEMBL29478885 | 1.00 | MAPK10 (1.00) | MAPK10MAPK9PTK2CDC7PLK4 | |
| Vs-4718 SCHEMBL30354503 | 0.99 | PTK2 (1.00) | MAPK10MAPK9PTK2CDC7PLK4 | |
| SCHEMBL15964228 | 0.92 | MAPK10 (0.85) | MAPK10MAPK9PTK2CDC7PLK4 | |
| SCHEMBL47302 | 0.92 | MAPK10 (0.84) | MAPK10MAPK9PTK2CDC7PLK4 | |
| SCHEMBL25270760 | 0.91 | MAPK10 (0.84) | MAPK10MAPK9PTK2EGFRALK | |
| SCHEMBL1231714 | 0.91 | MAPK10 (0.84) | MAPK10MAPK9PTK2ALK | |
| SCHEMBL1232326 | 0.91 | MAPK10 (0.83) | MAPK10MAPK9PTK2CDC7PLK4 | |
| SCHEMBL1231808 | 0.90 | MAPK10 (1.00) | MAPK10MAPK9PTK2CDC7PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250122222-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-119386004-A | Application of ginkgo biflavone enhanced VS4718 or panatinib in resisting esophageal squamous carcinoma progression | 北京肿瘤医院(北京大学肿瘤医院) | 2025-02-07 | — | — | CN | disclosed |
| US-20250034167-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2012006081-A1 | ORAL FORMULATION OF KINASE INHIBITORS | PONIARD PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2011019943-A1 | METHOD OF PROMOTING APOPTOSIS AND INHIBITING METASTASIS | PONIARD PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| WO-2009105498-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | PTK2 1/4885MAPK10 590/4885MAPK9 239/4885 |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | PTK2, JAK2, SRC | PTK2 1/4885MAPK10 386/4885MAPK9 173/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | PTK2 2255/4885MAPK10 590/4885MAPK9 658/4885 |
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | PTK2 996/4885MAPK10 505/4885MAPK9 483/4885 |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | PTK2 2724/4885MAPK10 926/4885MAPK9 977/4885 |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | PTK2 1858/4885MAPK10 542/4885MAPK9 294/4885 |
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | PTK2 863/4885MAPK10 519/4885MAPK9 559/4885 |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | PTK2 863/4885MAPK10 519/4885MAPK9 559/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | PTK2 3303/4885MAPK10 536/4885MAPK9 278/4885 |
| US-20250034167-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | PTK2 1024/4885MAPK10 455/4885MAPK9 469/4885 |
| US-20250122222-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | PTK2 636/4885MAPK10 391/4885MAPK9 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.